Analysts Set Traws Pharma, Inc. (NASDAQ:TRAW) PT at $1.00

Traws Pharma, Inc. (NASDAQ:TRAW) has earned a consensus recommendation of “Reduce” from the five analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $1.00.

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Traws Pharma in a report on Tuesday, August 18th. LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Citigroup cut Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TRAW. XTX Topco Ltd raised its stake in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Squadron Capital Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth about $806,000. Ikarian Capital LLC grew its holdings in Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after purchasing an additional 649,649 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Traws Pharma during the 4th quarter valued at about $220,000. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Stock Performance

Shares of TRAW opened at $0.57 on Friday. The stock has a market capitalization of $8.76 million, a PE ratio of -0.33 and a beta of 1.60. The company’s fifty day moving average is $0.61 and its 200 day moving average is $1.23. Traws Pharma has a fifty-two week low of $0.43 and a fifty-two week high of $3.27.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. As a group, research analysts forecast that Traws Pharma will post -1.2 earnings per share for the current year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.